Dayan et al., 2013 - Google Patents
Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9–16 years in BrazilDayan et al., 2013
View HTML- Document ID
- 16761954585291580232
- Author
- Dayan G
- Garbes P
- Noriega F
- de Sadovsky A
- Rodrigues P
- Giuberti C
- Dietze R
- Publication year
- Publication venue
- The American journal of tropical medicine and hygiene
External Links
Snippet
Immunogenicity and safety of a recombinant, live-attenuated, tetravalent dengue disease vaccine (CYD-TDV) was evaluated in children/adolescents in Brazil. In this observer-blind, placebo-controlled, phase II single-center study, children/adolescents (ages 9–16 years) …
- 229960005486 vaccines 0 title abstract description 51
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dayan et al. | Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9–16 years in Brazil | |
| Lanata et al. | Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru | |
| Paz-Bailey et al. | Dengue | |
| Silva et al. | Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella | |
| De la Cruz-Hernández et al. | Determination of viremia and concentration of circulating nonstructural protein 1 in patients infected with dengue virus in Mexico | |
| Schoepp et al. | Undiagnosed acute viral febrile illnesses, Sierra Leone | |
| Timiryasova et al. | Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development | |
| Fernandez et al. | An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques | |
| Tran et al. | Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children | |
| Gotuzzo et al. | Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years | |
| Dayan et al. | Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA | |
| Collaborative Group for Studies on Yellow Fever Vaccines | Duration of post-vaccination immunity against yellow fever in adults | |
| Pauvolid-Corrêa et al. | Neutralising antibodies for West Nile virus in horses from Brazilian Pantanal | |
| Watanaveeradej et al. | Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants | |
| Gibney et al. | Detection of anti-yellow fever virus immunoglobulin m antibodies at 3–4 years following yellow fever vaccination | |
| Amaya-Larios et al. | Seroprevalence of neutralizing antibodies against dengue virus in two localities in the state of Morelos, Mexico | |
| Martinez et al. | Safety and immunogenicity of a dengue virus serotype-1 purified-inactivated vaccine: results of a phase 1 clinical trial | |
| Feroldi et al. | Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: randomized, controlled phase 3 immunogenicity and safety trial | |
| Bosco-Lauth et al. | Pathogenesis of Japanese encephalitis virus infection in a golden hamster model and evaluation of flavivirus cross-protective immunity | |
| Hepburn et al. | Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine | |
| Angkasekwinai et al. | Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers | |
| Crum-Cianflone et al. | Vaccinations for the HIV-infected adult: a review of the current recommendations, part II | |
| Dubey et al. | Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: a randomized, observer-blind, placebo-controlled phase II trial | |
| Vasilakis et al. | Antigenic relationships between sylvatic and endemic dengue viruses | |
| Jelinek et al. | Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: an uncontrolled, open-label phase 3 study |